or Try an Advanced Search...

    Technical Analysis for ZNTL - Zentalis Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    D 3.32 21.61% 0.59
    ZNTL closed up 21.61 percent on Friday, November 1, 2024, on 1.31 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
    Earnings due: Nov 4
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical ZNTL trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Crossed Above 20 DMA Bullish 0.00%
    Crossed Above 50 DMA Bullish 0.00%
    MACD Bullish Signal Line Cross Bullish 0.00%
    Expansion Pivot Buy Setup Bullish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Wide Range Bar Range Expansion 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Oversold Stochastic Weakness 0.00%
    Stochastic Buy Signal Bullish 21.61%
    Older End-of-Day Signals for ZNTL ...

       Recent Intraday Alerts

    Alert Time
    Up 2 ATRs about 19 hours ago
    Possible Pocket Pivot about 20 hours ago
    Rose Above 20 DMA about 22 hours ago
    Up 10% about 22 hours ago
    Rose Above 10 DMA about 22 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    ZNTL Chart by TradingView
    Basic chart:

    Profile

    Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin Bunker on December 23, 2014 and is headquartered in New York, NY.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Drugs Breast Cancer Treatment Of Breast Cancer Epidermal Growth Factor Receptor Hormones Tyrosine Kinase Receptors Her2 Her2/Neu Estrogen Molecule Therapeutics Transcription Factors Antiestrogens Estrogen Receptor Receptor Positive Selective Estrogen Receptor Degraders Metastatic Breast Cancer

    Is ZNTL a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 22 Undervalued Opportunities: US Penny Stocks To Watch In October 2024
    Oct 18 State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings
    Oct 15 Several Insiders Invested In Zentalis Pharmaceuticals Flagging Positive News
    Oct 7 FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc
    Sep 19 Biotech Stock Roundup: GILD, NUVL Stocks Surge on Study Data, MRNA Down on Updates
    Sep 17 FDA lifts partial clinical hold on Zentalis Pharma’s cancer WEE1 inhibitor
    Sep 17 Zentalis Stock Up as FDA Lifts Partial Hold on Cancer Drug Studies
    Sep 16 Zentalis stock rises after FDA lifts partial clinical hold on azenosertib studies
    Sep 16 FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers
    Sep 16 Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies
    See more ZNTL news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 18.24
    52 Week Low 2.66
    Average Volume 2,141,488
    200-Day Moving Average 8.35
    50-Day Moving Average 3.30
    20-Day Moving Average 3.01
    10-Day Moving Average 3.00
    Average True Range 0.26
    RSI (14) 55.16
    ADX 12.86
    +DI 27.11
    -DI 16.64
    Chandelier Exit (Long, 3 ATRs) 2.70
    Chandelier Exit (Short, 3 ATRs) 3.45
    Upper Bollinger Bands 3.34
    Lower Bollinger Band 2.67
    Percent B (%b) 0.97
    BandWidth 22.23
    MACD Line -0.12
    MACD Signal Line -0.14
    MACD Histogram 0.0151
    Fundamentals Value
    Market Cap 234.94 Million
    Num Shares 70.8 Million
    EPS -4.56
    Price-to-Earnings (P/E) Ratio -0.73
    Price-to-Sales 0.00
    Price-to-Book 1.69
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.27
    Resistance 3 (R3) 4.17 3.75 4.11
    Resistance 2 (R2) 3.75 3.51 3.80 4.05
    Resistance 1 (R1) 3.54 3.36 3.65 3.64 4.00
    Pivot Point 3.12 3.12 3.18 3.17 3.12
    Support 1 (S1) 2.91 2.88 3.02 3.01 2.64
    Support 2 (S2) 2.49 2.73 2.54 2.59
    Support 3 (S3) 2.28 2.49 2.53
    Support 4 (S4) 2.38